⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know about hemophilia right now.

Know your exact type and severity. Hemophilia A is factor VIII deficiency; hemophilia B is factor IX deficiency. Severity is measured by factor level: severe (<1%), moderate (1–5%), or mild (5–40%). This single number drives every treatment decision.
Prophylaxis prevents joint damage. Regular preventive treatment — whether with factor concentrates, emicizumab, or other non-factor therapies — keeps factor levels high enough to avoid spontaneous bleeds. Starting early in childhood is key to protecting joints for life.
You have more options than ever. Beyond IV factor infusions, emicizumab (Hemlibra) is a subcutaneous injection for hemophilia A that works even in patients with inhibitors. Fitusiran (Qfitlia), concizumab (Alhemo), and marstacimab (Hympavzi) are newer subcutaneous options that work for both hemophilia A and B. Altuviiio allows once-weekly factor VIII dosing.
Gene therapy is a reality — with important caveats. Hemgenix (hemophilia B) is FDA-approved and commercially available. Roctavian (hemophilia A) was approved but was withdrawn from the US market in February 2026 due to low uptake. Gene therapy can produce endogenous factor from a single IV infusion, but durability is uncertain, not everyone qualifies, and the treatment costs $2–3.5 million.
Inhibitors are the most serious treatment complication. About 25–30% of severe hemophilia A and 3–5% of hemophilia B patients develop antibodies (inhibitors) that block factor therapy. Regular screening is essential, especially in the first 50 exposure days.
Comprehensive care at a Hemophilia Treatment Center changes outcomes. HTCs coordinate hematology, nursing, physical therapy, genetics, social work, and more. People treated at HTCs have 40% fewer hospitalizations and better joint health.
Treat bleeds promptly — "when in doubt, treat." For any suspected bleed, especially in the head, throat, abdomen, or joints, infuse factor (or use your prescribed breakthrough treatment) immediately and then seek medical attention. Do not wait for symptoms to worsen.
Most people with hemophilia worldwide lack adequate treatment. 75% of those affected globally receive inadequate or no care. Access to modern therapies varies dramatically by country and insurance coverage.

▼ Collapse

Overview — Understanding Hemophilia in 2026

Hemophilia is an inherited bleeding disorder caused by a deficiency in one of the clotting factors essential for normal blood coagulation. In hemophilia A, the missing or reduced protein is factor VIII; in hemophilia B, it is factor IX. Both are X-linked conditions, meaning they primarily affect males, though female carriers can also experience bleeding symptoms.

The hemophilia treatment landscape has been transformed over the past decade. Where patients once faced frequent, painful bleeds and progressive joint destruction, modern prophylaxis can prevent the vast majority of bleeds. The introduction of non-factor therapies has eliminated the need for IV access in many patients. Gene therapy offers the prospect of endogenous factor production from a single infusion. Yet challenges remain: inhibitor development can derail treatment, gene therapy durability is uncertain, and most people with hemophilia worldwide still lack access to adequate care.

Hemophilia A vs. Hemophilia B. While the two conditions share many features, they are becoming increasingly distinct in treatment. Hemophilia A (factor VIII deficiency) is about 4 times more common and has the widest range of treatment options including emicizumab, Altuviiio, and multiple gene therapy candidates. Hemophilia B (factor IX deficiency) has its own approved gene therapy (Hemgenix) and benefits from the longer natural half-life of factor IX, requiring less frequent infusions. Non-factor therapies like fitusiran (Qfitlia), concizumab (Alhemo), and marstacimab (Hympavzi) work for both types.

What has changed recently

Non-factor therapies have expanded rapidly. Emicizumab (Hemlibra, approved 2017) revolutionized hemophilia A prophylaxis. In 2024–2025, three more agents joined the landscape: marstacimab (Hympavzi, FDA October 2024) for hemophilia A/B without inhibitors, fitusiran (Qfitlia, FDA March 2025) for hemophilia A/B with or without inhibitors, and concizumab (Alhemo) for hemophilia A/B with or without inhibitors (initial inhibitor approval December 2024, expanded to without inhibitors July 2025). These subcutaneous therapies work through entirely different mechanisms than factor replacement.
Gene therapy has arrived — but adoption is slow. Hemgenix (CSL Behring) for hemophilia B remains commercially available with durability data now extending to 4+ years. Roctavian (BioMarin) for hemophilia A was withdrawn from the US market in February 2026 due to weak commercial uptake. Beqvez (Pfizer) for hemophilia B was FDA-approved but Pfizer discontinued it in February 2025 with zero commercial patients treated. Patient hesitancy, durability uncertainty, and high cost are driving the slow adoption.
Altuviiio (efanesoctocog alfa) has changed factor VIII therapy. This novel factor VIII product has a von Willebrand factor-independent half-life, enabling true once-weekly prophylaxis. In clinical trials, 78% of patients had zero bleeds by year 3.
Mim8 is advancing in clinical trials. This next-generation factor VIII mimetic — 15 times more potent than emicizumab in preclinical studies — is in phase 3 trials (FRONTIER program) with once-weekly or once-monthly dosing for hemophilia A with or without inhibitors.

According to the World Federation of Hemophilia 2024 Global Survey, approximately 75% of people with hemophilia worldwide receive inadequate or no treatment. In many low- and middle-income countries, factor concentrates are unavailable or unaffordable, diagnosis is delayed, and patients suffer preventable joint destruction and premature death.

Gene therapy pricing ($2–3.5 million per infusion) creates significant equity concerns. The WFH Humanitarian Aid Program provides donated factor products to developing nations, and organizations like the NHF advocate for improved access globally. Non-factor subcutaneous therapies may eventually help bridge some access gaps due to simpler administration and cold-chain requirements.

Do I have hemophilia A or B, and what is my severity classification (severe, moderate, or mild)?
What is my current prophylaxis plan, and is it optimal for my bleed rate and lifestyle?
Am I a candidate for non-factor therapies like emicizumab, fitusiran, or marstacimab?
Should I consider gene therapy? What are the eligibility requirements and realistic expectations?
Have I been tested for inhibitors recently? How often should this be checked?
Am I connected with a comprehensive hemophilia treatment center (HTC)?

If you are supporting someone with hemophilia, here are key things to know early on:

Learn to recognize bleeds. Joint bleeds (most common in ankles, knees, elbows) cause warmth, swelling, reduced range of motion, and a characteristic "tingling" or "bubbling" sensation that experienced patients learn to identify before visible swelling appears.
Master the treatment technique. Whether mixing and infusing factor concentrates intravenously or administering subcutaneous injections, hands-on training from your HTC nursing team is essential. Many families learn to treat at home.
Keep emergency supplies accessible. Factor concentrates or prescribed breakthrough treatments should be available at home, at school/work, and when traveling. Medical alert identification is recommended.
Coordinate with school and childcare. Work with your HTC social worker to develop a school health plan, train staff on bleed recognition, and ensure emergency treatment is available on-site.
Connect with the hemophilia community. Local chapters of the National Bleeding Disorders Foundation (formerly the National Hemophilia Foundation) and the Hemophilia Federation of America offer family support, educational events, and camp programs for children.

Diagnosis & Severity Classification

Hemophilia is typically suspected when a child has unusual bruising or prolonged bleeding, often discovered during circumcision, the eruption of teeth, or early mobility. A family history of bleeding is present in about two-thirds of cases; the remaining third arise from new (de novo) genetic mutations.

How hemophilia is diagnosed

The diagnostic pathway begins with screening tests and proceeds to specific factor assays:

Initial screening: A prolonged activated partial thromboplastin time (aPTT) with a normal prothrombin time (PT) suggests a deficiency in the intrinsic coagulation pathway. A mixing study (combining patient plasma with normal plasma) that corrects the aPTT points toward a factor deficiency rather than an inhibitor.
Specific factor assays: Factor VIII activity level confirms hemophilia A; factor IX activity level confirms hemophilia B. These are the definitive tests.
Genetic testing: DNA analysis of the F8 or F9 gene identifies the specific mutation, which helps predict severity, inhibitor risk, and enables carrier testing and prenatal diagnosis for family members. Inversion of intron 22 in the F8 gene accounts for about 45% of severe hemophilia A.

Severity classification

Severity is defined by baseline factor activity level and drives all treatment decisions:

Severity levels:
Severe (<1% factor activity): Spontaneous bleeds into joints and muscles, often starting in early childhood. Requires regular prophylaxis. Affects ~50–60% of hemophilia A patients.
Moderate (1–5%): Bleeds after minor trauma; occasional spontaneous bleeds. Prophylaxis often beneficial, especially with active lifestyle. Affects ~15–25%.
Mild (5–40%): Bleeds mainly after significant trauma or surgery. On-demand treatment usually sufficient; prophylaxis for specific situations. Affects ~25–30%.

Von Willebrand disease — an important distinction

Low factor VIII can also result from von Willebrand disease (VWD), which is far more common than hemophilia A and affects both sexes equally. VWD is caused by deficiency or dysfunction of von Willebrand factor, which carries and stabilizes factor VIII. Your hematologist will test for VWD before confirming a hemophilia A diagnosis.

Hemophilia follows X-linked inheritance: mothers who carry the gene have a 50% chance of passing it to each son (who would have hemophilia) and a 50% chance of passing it to each daughter (who would be a carrier). Daughters of men with hemophilia are obligate carriers.

Genetic counseling is recommended for all families. Carrier testing can identify the specific mutation and factor levels — importantly, some carriers have factor levels low enough to cause significant bleeding symptoms and may need treatment themselves. Prenatal testing (chorionic villus sampling or amniocentesis) and preimplantation genetic diagnosis are available for families who wish to know before birth.

What is my exact factor level, and what severity category does that place me in?
Has genetic testing been done to identify the specific mutation? What does it mean for inhibitor risk?
Should my family members (sisters, daughters, mother) be tested for carrier status?
Is my bleeding pattern consistent with my factor level, or could there be other contributing factors?
When and how often should I be screened for inhibitors?

Processing the diagnosis takes time. Parents of newly diagnosed children often feel guilt (carriers), fear, or overwhelm. This is normal. Your HTC team has supported many families through this transition.
Severity matters more than the label. "Hemophilia" sounds the same whether severe or mild, but the daily impact is vastly different. Ask your hematologist to explain specifically what your child's severity level means for daily life.
Early prophylaxis is the single most important intervention. For severe hemophilia, starting prophylaxis before or soon after the first joint bleed prevents the cycle of joint damage that defined hemophilia in previous generations.
Genetic counseling is for the whole family. Understanding inheritance helps relatives make informed decisions about testing and family planning.

Factor, Non-Factor & Gene Therapy

Hemophilia treatment has evolved from a single option (plasma-derived factor concentrates) to a diverse landscape of therapies with fundamentally different mechanisms. The goal is the same: prevent bleeds, protect joints, and enable a full, active life. The optimal choice depends on your hemophilia type, severity, inhibitor status, lifestyle, venous access, and personal preferences.

Factor replacement therapy — the established backbone

Factor concentrates remain the foundation of hemophilia treatment and are the only option for treating acute bleeds (even in patients on non-factor prophylaxis).

Standard half-life (SHL) vs. extended half-life (EHL) products:
SHL factor VIII products require infusion every 2–3 days; EHL products (e.g., Eloctate, Adynovate, Esperoct) extend this to every 3–5 days. For factor IX, SHL requires 2–3 times per week; EHL products (Alprolix, Idelvion, Rebinyn) allow once-weekly or less frequent dosing. EHL products maintain higher trough levels, providing better bleed protection between doses.

Altuviiio (efanesoctocog alfa) — once-weekly factor VIII

Altuviiio represents a step-change in factor VIII therapy. Unlike previous products whose half-life is limited by binding to von Willebrand factor, Altuviiio is engineered to have a VWF-independent half-life of approximately 48 hours — roughly 4 times longer than standard factor VIII. This enables true once-weekly prophylaxis at 50 IU/kg.

In the XTEND-1 trial, the annualized bleed rate was 0.70 in year 1, 0.62 in year 2, and 0.45 in year 3, with 78% of patients reporting zero bleeds by year 3. Real-world data from routine clinical practice is emerging and shows consistent benefit, particularly for patients switching from older EHL products.

Non-factor therapies — subcutaneous alternatives

These therapies work through mechanisms entirely different from replacing the missing clotting factor. They are given by subcutaneous injection, eliminating the need for IV access — a significant advantage for children and patients with difficult veins.

Emicizumab (Hemlibra) — hemophilia A only

Emicizumab is a bispecific antibody that mimics the function of factor VIII by bridging factor IXa and factor X. Given subcutaneously every 1, 2, or 4 weeks, it has dramatically reduced bleed rates in the HAVEN trials. It works in patients with and without inhibitors and has become the most widely used non-factor prophylaxis for hemophilia A. It does not work for hemophilia B because its mechanism is specific to the factor VIII cofactor role.

Fitusiran (Qfitlia) — hemophilia A and B

FDA-approved March 2025, fitusiran is a small interfering RNA (siRNA) that lowers antithrombin levels, thereby promoting thrombin generation and improving hemostasis. It is the first therapy approved for hemophilia A or B with or without inhibitors, administered subcutaneously as infrequently as once every two months (as few as 6 injections per year) via a prefilled pen. The ATLAS clinical trials showed significant reductions in bleed rates across all patient populations.

Concizumab (Alhemo) — hemophilia A and B, with or without inhibitors

Concizumab is a monoclonal antibody that blocks tissue factor pathway inhibitor (TFPI), a natural anticoagulant protein. By inhibiting TFPI, it allows more thrombin to be generated. It was first FDA-approved in December 2024 for hemophilia A and B with inhibitors, and the indication was expanded on July 31, 2025 to include hemophilia A and B without inhibitors (ages 12+), so it now covers both. It is given by daily subcutaneous injection via a prefilled pen. The explorer clinical trial program (explorer7 in patients with inhibitors, explorer8 without) demonstrated significant bleed reduction.

Marstacimab (Hympavzi) — hemophilia A and B, with or without inhibitors

Marstacimab is another anti-TFPI antibody. It was first FDA-approved in October 2024 for adults and adolescents (12+) with hemophilia A or B without inhibitors. On June 8, 2026, the FDA expanded its approval to include patients aged 6 and older with hemophilia A or B, with or without inhibitors (supported by the phase 3 BASIS and BASIS KIDS trials) — making it the first subcutaneous non-factor therapy available for children aged 6–11 with hemophilia B. Given once weekly by subcutaneous injection, it does not require routine treatment-related laboratory monitoring.

Gene therapy

Gene therapy for hemophilia uses a modified adeno-associated virus (AAV) vector to deliver a functional copy of the F8 or F9 gene to liver cells, enabling the body to produce its own clotting factor from a single intravenous infusion.

Current gene therapy landscape (mid-2026):
Hemgenix (etranacogene dezaparvovec, CSL Behring) for hemophilia B: FDA-approved November 2022. Uses AAV5 vector. The HOPE-B trial showed sustained factor IX activity at 4+ years with mean levels of 36–39% of normal. Price: $3.5 million. Commercially available but uptake has been low.
Roctavian (valoctocogene roxaparvovec, BioMarin) for hemophilia A: FDA-approved June 2023. Uses AAV5 vector. The GENEr8-1 trial showed factor VIII production, but levels declined 14–27% annually. BioMarin withdrew Roctavian from the US market in February 2026 (after failing to find a buyer following its October 2025 divestiture decision) due to weak commercial uptake ($26M total revenue); the EU authorization had already been withdrawn.
Beqvez (fidanacogene elaparvovec, Pfizer) for hemophilia B: FDA-approved 2024 but Pfizer discontinued all development and marketing in February 2025 with zero commercial patients treated, citing weak demand.

Why is gene therapy adoption so slow? Multiple factors contribute: uncertain long-term durability (will factor levels last 10, 20, 50 years?), the treatment is a one-time opportunity (re-dosing with the same AAV vector is not currently possible due to immune response), liver enzyme elevations requiring monitoring and sometimes immunosuppression, pre-existing AAV antibodies disqualify ~30–40% of candidates, the extremely high cost, and understandable patient hesitancy given the hemophilia community's historical experience with contaminated blood products.

There is no single "best" treatment. The right choice depends on multiple factors:

Hemophilia type: Emicizumab and Altuviiio are hemophilia A only. Non-factor agents (fitusiran, concizumab, marstacimab) and factor IX concentrates serve hemophilia B.
Inhibitor status: Patients with inhibitors have fewer options. Emicizumab, fitusiran (Qfitlia), and concizumab (Alhemo) work in the presence of inhibitors. Standard factor replacement does not.
Venous access: Subcutaneous options (emicizumab, fitusiran, concizumab, marstacimab) eliminate the need for IV infusions — a major quality-of-life advantage, especially for children.
Dosing frequency preference: Options range from daily (concizumab) to every 2 months (fitusiran). Altuviiio is once weekly IV; emicizumab can be every 4 weeks subcutaneously.
Activity level: Highly active patients or those participating in contact sports may benefit from higher trough factor levels achieved with pharmacokinetic-guided dosing or combination approaches.
Breakthrough bleed management: All patients on non-factor prophylaxis still need access to factor concentrates or bypassing agents for breakthrough bleeds or surgical coverage.

Given my hemophilia type, severity, and lifestyle, which prophylaxis approach do you recommend and why?
Am I a candidate for non-factor therapy? What are the advantages and risks compared to my current regimen?
If I am considering gene therapy, what screening tests do I need (AAV antibodies, liver function, HIV/HCV status)?
What is my target trough factor level, and is my current regimen achieving it?
If I switch to a non-factor therapy, what is my plan for treating breakthrough bleeds?
What is the monitoring schedule for my current therapy?

Factor infusion is a learnable skill. Most families learn to infuse at home with HTC nursing support. For young children, port-a-caths may be placed to provide reliable venous access until veins mature.
Subcutaneous therapies simplify daily life enormously. If your child qualifies for emicizumab, fitusiran, or marstacimab, the shift from IV infusions to subcutaneous injections can transform the daily routine and reduce treatment burden.
Treatment logs matter. Track every bleed, every treatment dose, and any side effects. These records help your hematologist optimize the regimen. Many HTCs provide apps or electronic tracking tools.
Travel planning requires preparation. Carry enough treatment supplies plus extra, keep products temperature-controlled, bring a letter from your HTC for airport security, and know the nearest HTC at your destination.

Living Well with Hemophilia

With modern treatment, people with hemophilia can expect to live full, active lives with near-normal life expectancy. The keys are consistent prophylaxis, joint protection, physical fitness, and comprehensive care coordination through your HTC.

Joint health — the central challenge

Repeated bleeds into joints cause hemophilic arthropathy — progressive cartilage destruction, synovial inflammation, and eventual joint deformity. The ankles, knees, and elbows are most commonly affected. Once established, joint damage is irreversible.

Prevention is everything. Prophylaxis started before or soon after the first joint bleed can prevent arthropathy entirely. This is the strongest argument for early, consistent preventive treatment.
Physiotherapy is essential. A hemophilia-experienced physiotherapist helps maintain range of motion, build muscle strength to protect joints, and design safe exercise programs.
Joint monitoring with ultrasound (HEAD-US). The Hemophilia Early Arthropathy Detection with Ultrasound scoring system can detect early joint changes before they become symptomatic, allowing treatment optimization.
Established arthropathy can be managed. Options include synovectomy (radiosynoviorthesis or arthroscopic), joint rehabilitation, pain management, and ultimately joint replacement for end-stage disease.

Physical activity and sports

Physical activity is strongly encouraged for people with hemophilia. Exercise strengthens muscles that protect joints, improves cardiovascular health, supports bone density, and enhances mental well-being.

Activity categories:
Recommended: Swimming, cycling, walking, yoga, tai chi, light weight training, elliptical machines.
Possible with adequate prophylaxis and protective equipment: Basketball, soccer, martial arts (non-contact forms), skiing, skateboarding.
Generally discouraged: Boxing, rugby, American football, wrestling, and other high-impact collision sports where head injuries and joint trauma are common.
Discuss your specific activity goals with your hematologist and physiotherapist — your prophylaxis regimen may need adjustment for higher-risk activities.

School, work, and daily life

School accommodations: Work with your HTC to create a school health plan. Staff should know how to recognize bleeds, when to administer treatment, and which activities require modification. Many children with hemophilia on prophylaxis participate fully in school with minimal restrictions.
Career considerations: Most careers are open to people with hemophilia. Occupations involving heavy manual labor or high injury risk may require additional planning. The HTC social worker can help with employment-related questions and accommodations.
Dental care: Regular dental care with a dentist aware of your condition is important. Some dental procedures require factor coverage. Avoid aspirin-containing products. Your HTC can provide a dental treatment letter.
Medications to avoid: Aspirin, ibuprofen, and other NSAIDs impair platelet function and increase bleeding risk. Use acetaminophen (Tylenol) for pain relief unless your hematologist specifically approves an NSAID with factor coverage. Always inform any new healthcare provider about your hemophilia.

Transition from pediatric to adult care

The transition from pediatric to adult hemophilia care is a critical period. Adolescents begin taking ownership of their treatment, learning self-infusion, understanding their condition, and managing insurance. This process should begin at age 12–14 and be completed by 18–25, with support from both pediatric and adult HTC teams.

Living with a chronic condition that requires ongoing treatment, activity modifications, and vigilance takes a psychological toll. Studies show higher rates of anxiety, depression, and reduced quality of life in people with hemophilia compared to the general population.

HTC psychologists and social workers provide specialized support
Peer support through hemophilia community organizations is highly valued by patients and families
Pain management for chronic joint disease should include psychological approaches alongside physical therapy
The fear of bleeds and the burden of treatment adherence are real stressors — acknowledging them is the first step

How are my joints? Have I had any imaging or HEAD-US assessment recently?
What exercise and sports are safe and recommended given my joint status and prophylaxis regimen?
Am I on the right pain management approach for my joint symptoms?
What should I do about dental procedures? Do I need factor coverage?
Are there medications I should specifically avoid?
How can I prepare for the transition to adult care (for adolescents)?

Normalize the condition without minimizing it. Children with hemophilia benefit from being treated as normally as possible while still maintaining necessary precautions. Overprotection can be as harmful as underprotection.
Encourage independence gradually. Self-infusion typically starts at age 10–12 when children are developmentally ready. This is a major milestone in building confidence and autonomy.
Insurance and financial navigation. Hemophilia treatment is expensive. HTC social workers are expert at navigating insurance coverage, copay assistance programs, manufacturer patient assistance, and 340B pharmacy programs. Don't try to manage this alone.
Build an emergency network. Ensure that grandparents, babysitters, coaches, and other caregivers know the basics: what hemophilia is, how to recognize a bleed, when to treat, and how to contact the HTC emergency line.

Inhibitors, Clinical Trials & Emerging Therapies

Inhibitors — the most serious complication

Inhibitors are antibodies developed by the immune system that neutralize infused clotting factor, rendering standard replacement therapy ineffective. They are the most challenging complication of hemophilia treatment.

Inhibitor facts:
• Develop in ~25–30% of severe hemophilia A patients and ~3–5% of hemophilia B patients
• Most commonly appear in the first 50 exposure days to factor concentrates, typically in early childhood
• Risk factors include: severe gene mutations (especially large deletions, nonsense mutations, intron 22 inversions), family history of inhibitors, African ancestry, and treatment-related factors (intensive early exposure, surgical context)
• Measured in Bethesda units (BU): low-titer (<5 BU) may still respond to high-dose factor; high-titer (≥5 BU) requires alternative approaches
• Regular inhibitor screening (Bethesda assay or Nijmegen modification) should be performed at defined intervals per WFH guidelines

Immune tolerance induction (ITI)

ITI is the primary approach to eliminating inhibitors in hemophilia A. It involves regular, often daily, high-dose factor VIII infusions over months to years to "teach" the immune system to tolerate the factor protein.

Success rates: Approximately 60–80% of hemophilia A patients achieve tolerance, with the best results in patients with lower-titer inhibitors who begin ITI early.
Protocols: The Bonn protocol (high-dose, 100–200 IU/kg twice daily) and the Malmö protocol (combined immunosuppression) are the two main approaches. The International ITI Study showed similar success rates with high-dose (200 IU/kg/day) and low-dose (50 IU/kg three times/week), but high-dose achieved tolerance faster.
During ITI: Patients need bleed protection with bypassing agents (rFVIIa/NovoSeven or aPCC/FEIBA) or non-factor therapies (emicizumab is increasingly used for prophylaxis during ITI).
Hemophilia B inhibitors are more complex: ITI success rates are lower, and some patients develop severe allergic/anaphylactic reactions to factor IX, requiring desensitization protocols.

Bypassing agents for patients with inhibitors

Recombinant factor VIIa (rFVIIa, NovoSeven): Activates clotting through an alternative pathway, bypassing the need for factor VIII/IX.
Activated prothrombin complex concentrate (aPCC, FEIBA): Contains a mixture of clotting factors that bypass the factor VIII/IX step. Important caution: aPCC use in patients on emicizumab carries a risk of thrombotic microangiopathy (TMA) and thrombosis — doses must be carefully managed.

Clinical trials and emerging therapies

Mim8 (Novo Nordisk): A next-generation factor VIII mimetic bispecific antibody that showed 15-fold greater potency than emicizumab in preclinical studies. Phase 3 FRONTIER trials are enrolling adults, adolescents, and children with hemophilia A, with or without inhibitors. Subcutaneous dosing once weekly or once monthly.
Next-generation gene therapy: Improved AAV vectors, lentiviral approaches, and gene editing (CRISPR/Cas9) are in preclinical and early clinical development, aiming for higher, more durable factor expression and the ability to treat patients with pre-existing AAV antibodies. LNP-based CRISPR delivery systems are a particularly promising approach.
Subcutaneous factor concentrates: Formulations that would allow factor VIII or IX to be given subcutaneously rather than intravenously are under development, potentially combining the reliability of factor replacement with the convenience of subcutaneous administration.
Novel RNA interference approaches: Beyond fitusiran, additional siRNA and antisense therapies targeting various components of the coagulation cascade are in development.
Combination approaches: Research into combining non-factor therapies with low-dose factor or using multiple rebalancing agents simultaneously is ongoing.

Your HTC is the best starting point for clinical trial information. Additionally:

ClinicalTrials.gov — search "hemophilia" for all registered trials
NHF and NBDF maintain lists of current hemophilia trials
WFH global clinical trial registry
Questions to ask about any trial: What is the study testing? What are the risks? What monitoring is required? Can I withdraw? Will I continue to have access to the treatment if it works?

Has my inhibitor titer been checked recently? What is the current level?
Am I a candidate for immune tolerance induction? What protocol would you recommend?
What non-factor therapy options are available to me while managing inhibitors?
Are there clinical trials I should consider? What are the potential benefits and risks?
If I am on emicizumab with inhibitors, what is the specific plan for using bypassing agents safely?

An inhibitor diagnosis is frightening but manageable. Modern non-factor therapies like emicizumab have transformed the outlook for inhibitor patients. The bleeds may continue during ITI, but effective prophylaxis is available.
ITI requires extraordinary commitment. Daily or near-daily infusions for months to years is demanding on families. Your HTC team can help with practical support, home nursing, and emotional resources.
Know the emergency protocols. Bypassing agent dosing is different from standard factor dosing and depends on which non-factor prophylaxis the patient is on. Keep written emergency instructions from your HTC visible and accessible.

Support & Resources

Utah and Intermountain West resources

Utah Center for Bleeding & Clotting Disorders (UCBCD), University of Utah Health: Federally funded comprehensive HTC providing multidisciplinary care for bleeding disorders. Offers diagnosis, prophylaxis management, inhibitor treatment, gene therapy evaluation, and clinical trial access.
Primary Children's Hospital Hemophilia Program: Regional pediatric referral center for children with bleeding disorders, including ITI programs and complex pediatric care.
Utah Bleeding Disorders Foundation (formerly Utah Hemophilia Foundation): State organization offering patient advocacy, educational programs, family support, and camp programs for children with bleeding disorders.
University of Utah Genetic Counseling: Carrier testing, family planning counseling, and prenatal diagnosis for hemophilia families.
Intermountain Health Hematology: Routine hemophilia care coordination for patients in the Intermountain network.

National organizations

National Bleeding Disorders Foundation (NBDF): bleeding.org — formerly the National Hemophilia Foundation (NHF; renamed 2023). Education, advocacy, research funding, patient services, financial assistance, policy advocacy, and local chapter support.
Hemophilia Federation of America (HFA): hemophiliafed.org — Peer support, educational symposia, and patient assistance.
World Federation of Hemophilia (WFH): wfh.org — Global guidelines, humanitarian aid program, treatment center directory.

Financial assistance and specialty pharmacy

Manufacturer patient assistance programs (Genentech/Roche for Hemlibra, Sanofi for Qfitlia, Novo Nordisk for Alhemo, Pfizer for Hympavzi, Sanofi/Sobi for factor products)
NHF and HFA financial assistance programs for copays, travel, and ancillary costs
340B pharmacy programs at HTCs can significantly reduce out-of-pocket costs
State hemophilia assistance programs (availability varies by state)
Patient advocacy organizations can help appeal insurance denials

Emergency preparedness

Every person with hemophilia should have:
• A medical alert bracelet or necklace identifying their condition and factor type
• An emergency treatment letter from their HTC (updated annually) with diagnosis, treatment plan, and 24/7 HTC contact number
• Factor concentrates or prescribed emergency treatment readily available at home, school/work, and when traveling
• The ability to self-infuse or a trained caregiver who can administer treatment
• Knowledge of the nearest HTC or emergency department familiar with bleeding disorders at any travel destination

Is there a comprehensive HTC closer to my home that I should be connected with?
Can the HTC social worker help me with insurance navigation and financial assistance?
Are there hemophilia camp programs available for my child?
How do I get an updated emergency treatment letter for travel?
What resources are available for the transition to adult care?

Your HTC is your home base. Build a strong relationship with the full team: hematologist, nurse coordinator, physical therapist, social worker, and psychologist. They are your partners in this journey.
Connect with other hemophilia families. NHF local chapters, HFA support groups, and hemophilia camps provide invaluable peer support. Other families who understand the daily reality of hemophilia are an irreplaceable resource.
Stay informed but grounded. The hemophilia treatment landscape is evolving rapidly. Your HTC team can help you evaluate new therapies and clinical trial opportunities in the context of your specific situation.
Advocate for your needs. Insurance coverage for hemophilia products can be complex and sometimes requires appeals. The HTC social worker and patient advocacy organizations can help you navigate the system.

International & Global Access

Hemophilia care varies dramatically across the globe. While patients in high-income countries increasingly benefit from non-factor therapies and gene therapy, the World Federation of Hemophilia estimates that approximately 75% of people with hemophilia worldwide lack adequate diagnosis and treatment. Understanding the global landscape helps contextualize both available resources and remaining gaps.

WFH Guidelines (3rd edition, 2020) — the global standard of care

The WFH Guidelines for the Management of Hemophilia (3rd edition, 2020) are the global source-of-record for hemophilia management. These evidence-based guidelines cover diagnosis, prophylaxis, inhibitor management, musculoskeletal care, surgical management, women and girls with bleeding disorders, and emerging therapies. They are freely available at wfh.org and are designed to be applicable across all resource settings, from high-income centers to developing-country clinics.

WFH Humanitarian Aid Program

The WFH Humanitarian Aid Program is the primary global mechanism for bridging the treatment gap. It provides donated factor concentrates, bypassing agents, and training to developing countries where these products are otherwise unavailable or unaffordable. The program works with national hemophilia organizations and treatment centers to build sustainable local capacity, including laboratory diagnosis, comprehensive care delivery, and physiotherapy services.

World Bleeding Disorders Registry (WBDR)

The WFH World Bleeding Disorders Registry (WBDR) is the global data backbone for hemophilia. This international registry tracks treatment access, clinical outcomes, inhibitor rates, and quality of life across participating countries. The WBDR provides the evidence base needed to advocate for improved treatment access and to measure the impact of humanitarian aid programs. Data from the WBDR informs health policy decisions and helps identify disparities in care delivery worldwide.

Gene therapy — global access and availability

Hemgenix (etranacogene dezaparvovec) for hemophilia B: Remains commercially available in the United States, but global uptake has been limited by cost ($3.5 million), patient hesitancy, and restrictive eligibility criteria. Access outside the US is extremely limited.
Roctavian (valoctocogene roxaparvovec) for hemophilia A: Was FDA-approved (June 2023) and received conditional EU marketing authorization, but BioMarin withdrew Roctavian from the European market and then from the US market in February 2026 due to very low commercial uptake.
Beqvez (fidanacogene elaparvovec) for hemophilia B: Received FDA approval in 2024, but Pfizer discontinued all development, manufacturing, and commercialization in February 2025 with zero commercial patients treated, citing insufficient demand.

Non-factor therapy access

Non-factor therapies, particularly emicizumab (Hemlibra), have expanded treatment access in many countries due to subcutaneous administration (no IV access or cold chain required for some products) and less frequent dosing. Emicizumab is now approved in more than 100 countries. However, newer non-factor therapies (fitusiran, concizumab, marstacimab) are currently available primarily in the United States, with regulatory submissions underway in other regions. Gene therapies remain available only in the US and select specialized centers, with no near-term prospect of broad global access given pricing and infrastructure requirements.

Are there newer therapies approved in other countries that might become available here?
Can the WFH Treatment Centre Directory help me find specialized care if I travel or relocate internationally?
Is our treatment center connected with any international research networks or registries?
Are there humanitarian aid programs or compassionate access programs I should know about?

Failed & De-Adopted Therapies

Knowing what has been tried and did not work is important. Understanding past failures helps patients and caregivers evaluate new options with realistic expectations and avoids pursuing approaches that have already proven unsafe or ineffective.

WITHDRAWN BioMarin’s Roctavian was FDA-approved in June 2023 as the first gene therapy for hemophilia A. However, factor VIII expression declined significantly over time in many patients, falling below prophylactic levels by year 3–4 in a substantial proportion. Commercial uptake was extremely poor — fewer than 30 patients were treated commercially worldwide. BioMarin announced it was divesting the product in 2025, and the EU marketing authorization was withdrawn. The experience highlighted the challenge of durable factor VIII gene therapy due to the large FVIII gene and episomal AAV vector biology.

WITHDRAWN Pfizer’s Beqvez received FDA approval in April 2024 as a one-time gene therapy for hemophilia B. Despite positive clinical data, Pfizer discontinued the product in February 2025 with zero commercial patients treated, citing unsustainable market conditions and competition from Hemgenix. The withdrawal underscored the commercial challenges facing ultra-high-cost one-time therapies in a disease with effective existing treatments.

DE-ADOPTED The original fitusiran clinical development (developed by Alnylam and Sanofi; later approved as Qfitlia) was temporarily placed on clinical hold in 2017 after a fatal cerebral sinus venous thrombosis in a patient who received concomitant bypassing agents. The program was redesigned with revised dosing guidelines and concomitant treatment restrictions. Fitusiran was eventually approved in 2025 under the brand name Qfitlia with a reformulated safety protocol, but the initial formulation and dosing approach were abandoned. The episode demonstrated the thrombotic risk inherent in antithrombin-lowering strategies when combined with procoagulant therapies.

DE-ADOPTED Before purified factor concentrates became available in the 1970s, cryoprecipitate (a plasma-derived product rich in factor VIII and fibrinogen) was the standard treatment for hemophilia A. It was replaced by lyophilized factor concentrates that offered standardized dosing, viral inactivation, and easier storage. The HIV/hepatitis tragedy of the 1980s — when contaminated plasma products infected thousands of hemophilia patients — accelerated the move to recombinant products. While cryoprecipitate remains available in some resource-limited settings, it is no longer recommended as primary therapy in any major guideline due to infection risk and dosing imprecision.

DE-ADOPTED Desmopressin (DDAVP) stimulates the release of stored factor VIII and von Willebrand factor from endothelial cells. While it remains useful for mild hemophilia A and some moderate cases, its use in severe hemophilia A was abandoned because patients with very low baseline FVIII levels have insufficient stores to release. It is also ineffective in hemophilia B (does not affect factor IX). Repeated doses cause tachyphylaxis (diminishing response), and it carries a risk of hyponatremia and, rarely, thrombosis. It is now limited to mild hemophilia A and certain surgical situations where a trial dose confirms adequate response.

DE-ADOPTED For decades, patients with severe hemophilia were treated only when bleeds occurred (on-demand or episodic therapy). Landmark studies in the 1990s and 2000s — including the US Joint Outcome Study (2007) — demonstrated that prophylactic treatment started early in childhood dramatically reduced joint bleeds and preserved joint function compared to on-demand therapy. All major guidelines (WFH, ASH, MASAC) now recommend prophylaxis as the standard of care for severe hemophilia. On-demand treatment alone is considered suboptimal and is associated with progressive, irreversible arthropathy.

FAILED During the HAVEN 1 trial of emicizumab in hemophilia A patients with inhibitors, several patients who received activated prothrombin complex concentrate (aPCC/FEIBA) for breakthrough bleeds while on emicizumab developed thrombotic microangiopathy (TMA) and thrombotic events. The combination of aPCC’s procoagulant activity with emicizumab’s factor VIII mimetic effect generated excessive thrombin. As a result, current guidelines strictly limit aPCC dosing in emicizumab-treated patients (no more than 100 U/kg in the first 24 hours, avoid if possible), and recombinant factor VIIa (rFVIIa) is the preferred bypassing agent. This safety signal fundamentally changed breakthrough bleed management in emicizumab-treated patients.

Hemophilia, Carriers & Pregnancy

Hemophilia A and B are X-linked recessive conditions that primarily affect males. Women with one copy of the affected gene are carriers and may have factor levels ranging from normal to significantly reduced, depending on which X chromosome is expressed in their cells (a process called lyonization).

Carrier testing and genetic counseling

Daughters of men with hemophilia are obligate carriers (they definitely carry one copy of the affected gene). They should have genetic testing to confirm their factor level and discuss family planning options with a genetic counselor and hematologist.
Daughters of carrier women have a 50% chance of being a carrier; sons have a 50% chance of having hemophilia. Genetic testing can clarify carrier status.
Preimplantation genetic testing (PGT) — available for hemophilia through specialist reproductive genetics centers, allowing identification of unaffected embryos before IVF transfer.
Prenatal diagnosis — chorionic villus sampling (CVS at 10-13 weeks) or amniocentesis (15-20 weeks) can determine whether a male fetus has hemophilia or whether a female fetus is a carrier.

Bleeding risk in carrier women

Some carrier women have reduced factor levels (below 50%) and may experience bleeding symptoms including heavy menstrual periods, bruising, and prolonged bleeding after injury or surgery. If you are a known hemophilia carrier, your factor levels should be measured before any procedure or delivery.

Pregnancy in carrier women

Factor VIII (hemophilia A) levels typically rise naturally during pregnancy (often to near-normal levels by the third trimester), which may reduce bleeding risk during delivery for most carriers. However, levels fall rapidly after delivery, increasing postpartum hemorrhage risk.
Factor IX (hemophilia B) does not rise as much during pregnancy, so carriers may remain at higher bleeding risk throughout.
All carrier women should be monitored by both a hematologist and a maternal-fetal medicine specialist during pregnancy.
A clear plan for delivery should be in place: factor replacement may be needed; epidural anesthesia timing depends on factor levels; delivery should occur at a center capable of managing bleeding complications.
Postpartum hemorrhage is a significant risk, especially for factor IX carriers. Factor replacement and antifibrinolytic agents (tranexamic acid) may be needed immediately after delivery.

If your baby may have hemophilia

Avoid fetal scalp electrodes and vacuum delivery (trauma risk for a baby with hemophilia).
Test cord blood immediately after delivery to determine the newborn's factor level.
If hemophilia is confirmed, the newborn should be evaluated by a pediatric hematologist before any circumcision or invasive procedures.
The baby should receive a vitamin K injection (as recommended for all newborns) — this is safe and does not worsen hemophilia.

Tell your obstetrician and delivery team early in pregnancy that you are a hemophilia carrier. A written delivery plan reviewed by your hematologist and obstetric team is strongly recommended.

Glossary of Key Terms

Factor VIII (FVIII): The clotting protein that is deficient or absent in hemophilia A. It acts as a cofactor to factor IXa in the intrinsic coagulation pathway, accelerating the activation of factor X.
Factor IX (FIX): The clotting protein that is deficient or absent in hemophilia B. It is a serine protease that, when activated (FIXa), works with factor VIII to activate factor X.
Hemophilia A: An X-linked bleeding disorder caused by deficiency of factor VIII. Approximately 1 in 5,000 male births. Also called "classic hemophilia."
Hemophilia B: An X-linked bleeding disorder caused by deficiency of factor IX. Approximately 1 in 25,000 male births. Also called "Christmas disease."
Inhibitor (alloantibody): An antibody produced by the patient's immune system that binds to and neutralizes infused clotting factor, making standard replacement therapy partially or completely ineffective. The most serious treatment complication in hemophilia.
Bethesda units (BU): The unit of measurement for inhibitor titer (strength). One Bethesda unit is the amount of inhibitor that neutralizes 50% of factor activity in a test mixture. Low-titer is <5 BU; high-titer is ≥5 BU.
Prophylaxis vs. on-demand treatment: Prophylaxis is regular, scheduled treatment given to prevent bleeds before they occur. On-demand (episodic) treatment is given only when a bleed happens. Prophylaxis is the standard of care for severe hemophilia because it prevents joint damage.
EHL (extended half-life): Factor concentrate products engineered to remain active in the bloodstream longer than standard products, allowing less frequent infusions. Examples include Eloctate, Adynovate, and Esperoct (factor VIII) and Alprolix, Idelvion, and Rebinyn (factor IX).
SHL (standard half-life): Conventional factor concentrate products with a typical half-life of 8–12 hours for factor VIII and 18–24 hours for factor IX, requiring more frequent infusions than EHL products.
Non-factor therapy: Any hemophilia prophylaxis that works through a mechanism other than replacing the missing clotting factor. These include emicizumab (factor VIII mimetic), fitusiran (antithrombin lowering), concizumab and marstacimab (anti-TFPI). Given subcutaneously.
Emicizumab (Hemlibra): A bispecific monoclonal antibody that bridges factor IXa and factor X, mimicking the cofactor function of factor VIII. Used for prophylaxis in hemophilia A with or without inhibitors. Subcutaneous injection every 1, 2, or 4 weeks.
Fitusiran (Qfitlia): A small interfering RNA (siRNA) that lowers antithrombin levels to rebalance hemostasis. FDA-approved March 2025 for hemophilia A or B, with or without inhibitors. Subcutaneous injection as infrequently as every 2 months.
Concizumab (Alhemo): A monoclonal antibody that blocks tissue factor pathway inhibitor (TFPI), promoting thrombin generation. FDA-approved for hemophilia A and B, with or without inhibitors (initial approval December 2024 for inhibitors; expanded July 31, 2025 to without inhibitors). Daily subcutaneous injection.
ITI (immune tolerance induction): A treatment protocol using regular, high-dose factor infusions over months to years to eliminate inhibitors by teaching the immune system to tolerate the clotting factor protein. Success rate approximately 60–80% in hemophilia A.
HTC (hemophilia treatment center): A federally funded or recognized comprehensive care center specializing in bleeding disorders. HTCs provide multidisciplinary care including hematology, nursing, physical therapy, social work, psychology, and genetic counseling. People treated at HTCs have 40% fewer hospitalizations.
ABR (annualized bleed rate): The average number of bleeds a patient experiences per year. This is the primary outcome measure in hemophilia clinical trials and the key metric used to evaluate prophylaxis effectiveness.
Joint score (HJHS): The Hemophilia Joint Health Score is a standardized physical examination tool used to assess the condition of joints affected by hemophilia. It evaluates swelling, muscle atrophy, joint crepitus, range of motion, and pain in six index joints (elbows, knees, ankles). Scores range from 0 (normal) to 124 (maximum impairment).

Specialty Center Directory

How to choose a center. Your primary care should be at a federally funded Hemophilia Treatment Center (HTC) — they coordinate hematology, nursing, PT, social work, and genetic counseling under one roof. For routine prophylaxis management, an HTC within driving distance is ideal. Seek a regional academic HTC for inhibitor management (ITI), gene therapy evaluation, or clinical trial enrollment. Veterans with hemophilia are eligible for VA hematology services, which coordinate with HTCs for specialized care. For rare complications or failed ITI, consider referral to a national center of excellence with dedicated inhibitor programs.

Mountain West / Utah

Utah Center for Bleeding & Clotting Disorders (UCBCD), University of Utah Health: Federally funded comprehensive HTC providing full-spectrum bleeding disorder care including diagnosis, prophylaxis management, inhibitor treatment, gene therapy evaluation, clinical trial enrollment, genetic counseling, and multidisciplinary support (hematology, nursing, PT, social work, psychology). Phone: 801-581-2121 (U of U Health main).
Primary Children’s Hospital Hemophilia Program: Regional pediatric referral center for children with hemophilia and other bleeding disorders. Provides specialized pediatric hematology, immune tolerance induction programs, complex surgical management with factor coverage, and transition planning to adult care. Phone: 801-662-1000.
Intermountain Health Hematology: Routine hemophilia care coordination for patients in the Intermountain network across Utah and the Mountain West region. Phone: 801-442-2000 (Intermountain Health main).

Veterans

George E. Wahlen VA Medical Center (Salt Lake City): Provides hematology services for veterans with bleeding disorders. Coordinates with the University of Utah HTC for specialized hemophilia care including prophylaxis management, inhibitor evaluation, and referral for gene therapy candidacy assessment. Phone: 801-582-1565.
VA Hemophilia Care Coordination: Veterans enrolled in VA healthcare can access hemophilia treatment through VA hematology with referral to federally funded HTCs for comprehensive multidisciplinary care. Contact your local VA medical center or the VA Health Benefits Hotline at 1-877-222-8387.

United States — National

National Bleeding Disorders Foundation (NBDF): bleeding.org — the largest US patient organization for bleeding disorders (formerly the National Hemophilia Foundation, NHF; renamed 2023, and hemophilia.org now redirects here). Operates a network of local chapters providing education, advocacy, financial assistance, camp programs, and peer support, plus the Steps for Living education program and MASAC medical recommendations. Chapter locator on their website. Phone: 1-212-328-3700.
CDC-funded Hemophilia Treatment Centers: The Centers for Disease Control and Prevention funds a national network of approximately 150 HTCs providing comprehensive, multidisciplinary hemophilia care organized into regional networks. Find your nearest HTC through the CDC or NBDF directories.
Hemophilia Federation of America (HFA): hemophiliafed.org — Peer support, educational symposia, patient assistance programs, and advocacy. Phone: 1-202-675-6984.

Canada

Canadian Hemophilia Society (CHS): hemophilia.ca — National organization providing advocacy, education, research funding, and support services. Operates provincial chapters across Canada for local support. Phone: 1-514-848-0503.
St. Michael’s Hospital Hemophilia Program (Toronto): One of Canada’s largest comprehensive bleeding disorders programs, offering adult hemophilia care, inhibitor management, gene therapy evaluation, and clinical trial access.
Hospital for Sick Children (SickKids, Toronto): Leading pediatric hemophilia center with expertise in ITI, prophylaxis optimization, and transition to adult care.
Centre hospitalier universitaire Sainte-Justine (Montreal): Major francophone pediatric hemophilia center; comprehensive bleeding disorders program.
St. Paul’s Hospital Hemophilia Program (Vancouver): Western Canada’s largest adult comprehensive bleeding disorders center with clinical trial access.

International

World Federation of Hemophilia (WFH): wfh.org — The global umbrella organization for hemophilia. Publishes the WFH Guidelines (3rd edition, 2020), operates the Humanitarian Aid Program, maintains the World Bleeding Disorders Registry, and coordinates the WFH Treatment Centre Directory for finding specialized care worldwide.
WFH Treatment Centre Directory: A searchable global directory of hemophilia treatment centers, available at wfh.org. Essential for patients traveling internationally or relocating to find qualified care at their destination.
Royal Free Hospital Haemophilia Centre (London, UK): One of Europe’s largest and oldest comprehensive haemophilia centres, offering specialized inhibitor management, gene therapy trials, and multidisciplinary care for complex bleeding disorders.
Universitätsklinikum Bonn — Institut für Experimentelle Hämatologie und Transfusionsmedizin (Bonn, Germany): World-renowned center that developed the Bonn ITI protocol; major hub for hemophilia gene therapy research and comprehensive care in Europe.
Nara Medical University Hemophilia Center (Nara, Japan): Leading hemophilia treatment and research center in Asia with expertise in non-factor therapies and gene therapy evaluation. Japan has been an early adopter of several non-factor agents.
European Association for Haemophilia and Allied Disorders (EAHAD): eahad.org — The European professional organization for healthcare providers treating bleeding disorders. Publishes clinical guidelines, organizes the annual EAHAD Congress, and supports the EUHANET center certification program.

class="content-section" data-stage="resources">

Clinical Trials & Next-Generation Research

The hemophilia research pipeline remains active despite the commercial setbacks of first-generation gene therapies. Several programs are advancing through clinical trials that may further transform treatment over the next 3–5 years.

Mim8 — next-generation factor VIII mimetic

Mim8 (Novo Nordisk) is a next-generation bispecific antibody that mimics the cofactor function of factor VIII, similar in concept to emicizumab but with significantly enhanced potency. Preclinical studies demonstrated approximately 15-fold greater potency than emicizumab. Mim8 is administered subcutaneously with potential dosing of once weekly or once monthly.

The FRONTIER phase 3 clinical trial program is evaluating Mim8 (international nonproprietary name denecimig) in hemophilia A patients, with or without inhibitors, across age groups:

FRONTIER2 (NCT05053139): Adults and adolescents aged 12 and older, with or without inhibitors. The 26-week results were published in the New England Journal of Medicine (2025), showing significant annualized bleeding-rate reduction with once-weekly or once-monthly subcutaneous dosing.
FRONTIER3 (NCT05306418): Children below age 12 (ages 1–11), with or without inhibitors; the majority achieved zero treated bleeds.
FRONTIER4: open-label long-term extension evaluating once-every-two-weeks dosing and long-term safety across all regimens.

Novo Nordisk submitted a Biologics License Application to the FDA for Mim8 in 2025; it remains investigational pending review. If approved, Mim8 could offer an alternative or successor to emicizumab with potentially greater bleed protection and more convenient (including once-monthly) dosing.

Next-generation gene therapy approaches

Despite the challenges faced by first-generation AAV-based gene therapies (durability concerns, immune responses, high cost), research continues actively:

Improved AAV vectors: Engineered capsids designed for higher liver transduction efficiency, reduced immunogenicity, and the potential to treat patients with pre-existing AAV antibodies (who are currently excluded).
Lentiviral approaches: Lentiviral vectors can integrate into the host genome, potentially providing more durable expression than episomal AAV. Early-stage clinical trials are underway.
CRISPR/Cas9 gene editing: Direct correction of the mutated F8 or F9 gene rather than adding a new copy. LNP (lipid nanoparticle)-based CRISPR delivery systems are a particularly promising approach that could avoid the immunogenicity issues of viral vectors. Currently in preclinical and early clinical development.
Re-dosing strategies: Research into immunomodulation protocols and alternative AAV serotypes that could allow patients to receive a second gene therapy dose if factor levels decline after the first infusion.

Key active and recent clinical trials (selected NCT numbers)

HOPE-B (NCT03569891): Hemgenix gene therapy for hemophilia B; long-term follow-up ongoing with 4+ year durability data.
GENEr8-1 (NCT03370913): Roctavian gene therapy for hemophilia A; pivotal trial (product now withdrawn from the US market).
XTEND-1 (NCT04161495): Altuviiio (efanesoctocog alfa) once-weekly factor VIII; pivotal phase 3; Year 3 extension (XTEND-ed, NCT04644575) data showed 78% zero bleeds.
ATLAS-INH (NCT03417102): Fitusiran (Qfitlia) in hemophilia A/B with inhibitors; supported FDA approval.
ATLAS-A/B (NCT03417245): Fitusiran in hemophilia A/B without inhibitors.
explorer7 (NCT04083781): Concizumab (Alhemo) in hemophilia A/B with inhibitors.
BASIS (NCT03938792): Marstacimab (Hympavzi) in hemophilia A/B without inhibitors; supported FDA approval.

Long-term data for newer non-factor therapies

Fitusiran (Qfitlia): The ATLAS long-term extension studies (NCT03754790) continue to accumulate safety and efficacy data beyond the pivotal trials. Key areas of ongoing monitoring include thromboembolic event rates, liver function, and sustained bleed reduction over multiple years of use.
Concizumab (Alhemo): Long-term follow-up from the explorer trials is evaluating durability of bleed protection, safety in the inhibitor population, and real-world treatment patterns.

Finding hemophilia clinical trials

How to search for hemophilia clinical trials:
• ClinicalTrials.gov: Visit clinicaltrials.gov and search for "hemophilia A" or "hemophilia B." Filter by status (recruiting), phase, age group, and location. Bookmark your search to check for new trials periodically.
• Your HTC: Your hemophilia treatment center is the best starting point. HTC physicians are aware of trials their center participates in and can assess your eligibility.
• NBDF/NHF: The National Bleeding Disorders Foundation and National Hemophilia Foundation maintain curated lists of currently enrolling hemophilia trials.
• WFH Clinical Trials Registry: The WFH maintains a global registry of hemophilia clinical trials, searchable by country and therapy type.
• Manufacturer websites: Pharmaceutical companies running hemophilia trials (Novo Nordisk, Roche/Genentech, Sanofi, Pfizer, CSL Behring, BioMarin, uniQure) post trial information and enrollment contacts on their clinical trial pages.

What is the trial testing, and what phase is it in?
What are the eligibility requirements, and do I qualify?
What are the known risks and potential benefits?
How often would I need to visit the trial site, and is travel support available?
Is there a placebo arm, or will all participants receive the active treatment?
What monitoring and follow-up is required?
Can I withdraw from the trial if I choose, and what happens to my care?
If the therapy works, will I continue to have access after the trial ends (compassionate use or open-label extension)?